Drug–Drug Interaction between Tacrolimus and Vonoprazan in Kidney Transplant Recipients

Blood concentrations of tacrolimus upon conversion from rabeprazole to vonoprazan in renal transplant recipients: Correlation with cytochrome P450 gene polymorphisms

(2021) Shogo Watari et al.   Drug Metabolism and Pharmacokinetics

Effects of Concomitant Administration of Vonoprazan Fumarate on the Tacrolimus Blood Concentration in Kidney Transplant Recipients

(2020) Takanori Mei et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients

(2018) Jennifer Trofe-Clark et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Early conversion of pediatric kidney transplant patients to everolimus with reduced tacrolimus and steroid elimination: Results of a randomized trial

(2018) Burkhard Tönshoff et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials

(2016) H. Miwa et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study

(2016) Helen Jenkins et al.   CLINICAL DRUG INVESTIGATION

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy forHelicobacter pylorieradication: a phase III, randomised, double-blind study

(2016) Kazunari Murakami et al.   GUT

In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker

(2016) Hitomi Yamasaki et al.   XENOBIOTICA

Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis

(2015) K. Ashida et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines forCYP3A5Genotype and Tacrolimus Dosing

(2015) KA Birdwell et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects

(2015) Yuuichi Sakurai et al.   Clinical and Translational Gastroenterology

Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation

(2012) Robert M Langer et al.   TRANSPLANT INTERNATIONAL

1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related Diseases

(2010) Y. Hori et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Pharmacokinetics for Once- Versus Twice-Daily Tacrolimus Formulations inDe NovoKidney Transplantation: A Randomized, Open-Label Trial

(2009) Z. Wlodarczyk et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference

(2009) Pierre Wallemacq et al.   THERAPEUTIC DRUG MONITORING

Interaction between Tacrolimus and Lansoprazole, but not Rabeprazole in Living-Donor Liver Transplant Patients with Defects of CYP2C19 and CYP3A5

(2008) Keiko Hosohata et al.   Drug Metabolism and Pharmacokinetics